Results

Professionally Managed Portfolios

10/01/2024 | Press release | Distributed by Public on 10/01/2024 10:28

Summary Prospectus by Investment Company - Form 497K

Document

Villere Balanced Fund
TICKER: VILLX
Supplement dated October 1, 2024 to the Summary Prospectus dated
December 29, 2023
On August 14-15, 2024, the Board of Trustees (the "Board") of the Trust approved an amendment to the operating expense limitation agreement between the Trust, on behalf of the Villere Balanced Fund ("Balanced Fund") and St. Denis J. Villere & Company, LLC (the "Adviser"), pursuant to which the Adviser has agreed to reduce the Balanced Fund's operating expense limit from 0.99% to 0.89%, effective October 1, 2024.

The relevant information under the section entitled "Summary Section - Villere Balanced Fund, is deleted and replaced with the following:

Fees and Expenses of the Fund
This table describes the fees and expenses that you may pay if you buy, hold and sell shares of the Balanced Fund. You may pay other fees, such as brokerage commissions and other fees to financial intermediaries, which are not reflected in the table and expense example below.
Shareholder Fees
(fees paid directly from your investment)
None
Annual Portfolio Operating Expenses
(expenses that you pay each year as a percentage of the value of your investment)
Management Fee 0.75%
Distribution and Service (12b-1) Fee None
Other Expenses 0.30%
Acquired Fund Fees and Expenses(1)
0.00%
Total Annual Fund Operating Expenses 1.05%
Fee Waiver and/or Expense Reimbursement(2)
-0.16%
Total Annual Fund Operating Expenses after Fee Waiver and/or Expense Reimbursement(2)
0.89%
(1)Acquired Fund Fees and Expenses ("AFFE") are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, including money market funds and other mutual funds, closed end funds, business development companies or certain exchange-traded funds. Please note that the amount of Total Annual Fund Operating Expenses shown in the above table will differ from the "Financial Highlights" section of the Prospectus, which reflects the operating expenses of the Fund and does not include indirect expenses such as AFFE.
(2)St. Denis J. Villere & Company (the "Adviser") has contractually agreed to reduce its fees and/or pay Fund expenses (excluding acquired fund fees and expenses, interest expense in connection with investment activities, taxes, and extraordinary expenses) in order to limit Total Annual Fund Operating Expenses After Fee Waiver and/or Expense Reimbursement to 0.89% of the Fund's average daily net assets (the "Expense Cap"). The Expense Cap is indefinite, but will remain in effect until at least October 1, 2025. The Expense Cap may be terminated at any time by the Trust's Board of Trustees (the "Board") upon 60 days' notice to the Adviser, or by the Adviser with consent of the Board. The Adviser is permitted, with Board approval, to be
1

reimbursed for fee reductions and/or expense payments made in the prior three years from the date the fees were waived and/or expenses were paid. This reimbursement may be requested if the aggregate amount actually paid by the Fund toward operating expenses for such period (taking into account any reimbursement) does not exceed the lesser of the Expense Caps in place at the time of waiver or at the time of reimbursement.

Example
This Example is intended to help you compare the cost of investing in the Balanced Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Balanced Fund for the time periods indicated and then redeem (sell) all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Balanced Fund's operating expenses remain the same (taking into account the contractual Expense Cap for the first year only). Although your actual costs may be higher or lower, based on these assumptions your costs would be:
One Year Three Years Five Years Ten Years
$91 $318 $564 $1,268






























Please retain this Supplement with your Summary Prospectus.
2